Favipiravir quickens recovery, show trials | Health - Hindustan Times
close_game
close_game

Favipiravir quickens recovery, show trials

Hindustan Times, New Delhi | By
Jul 23, 2020 01:04 AM IST

One of the principal investigators said that they have observed patients randomised to favipiravir seemed to have a faster clinical cure.

Glenmark’s favipiravir hastens recovery among mild to moderate coronavirus disease (Covid-19) cases, the pharma major said as it announced results of its phase III clinical trials on Wednesday.

A lab technician wearing a full-face mask and a protective suit holds tablets of investigational coronavirus disease (Covid-19) treatment drug Favipiravir.(REUTERS/ For Representative Purposes Only)
A lab technician wearing a full-face mask and a protective suit holds tablets of investigational coronavirus disease (Covid-19) treatment drug Favipiravir.(REUTERS/ For Representative Purposes Only)

“Results from the Phase 3 trial showed numerical improvements for the primary efficacy endpoint with 28.6% faster viral clearance in the overall population as measured by the median time until cessation of oral shedding of virus in the Favipiravir treatment arm compared to those in the control arm…,” the company said in a statement.

Hindustan Times - your fastest source for breaking news! Read now.

“…40% faster achievement of clinical cure defined as the physician’s assessment of normalization of clinical signs – temperature, oxygen saturation, respiratory rate and cough with a statistically significant reduction in median time to clinical cure in the Favipiravir treatment arm (3 days)…, compared to the control arm (5 days)….”, the statement said. Favipiravir is a broad-spectrum oral antiviral drug that inhibits the Sars-Cov-2 virus, which causes Covid-19, from replicating.

Click here for the complete coverage of the Covid-19 pandemic

The India trials were conducted on 150 patients across seven clinical sites in India. The open-label randomized, multicenter clinical trial, evaluated the efficacy and safety of favipiravir plus standard supportive care (favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate cases.

“We are encouraged with the results and these indicate that early treatment with favipiravir may improve clinical outcomes for mild to moderate patients and could prevent patients from progressing to acute respiratory distress syndrome and mortality,” said Monika Tandon, vice president, and head, clinical development, Glenmark.

One of the principal investigators of the study, Dr Zarir Udwadia, said, “…I have had a chance to independently view the initial results and they are encouraging: Patients randomised to favipiravir seemed to have a faster clinical cure, and faster viral clearance than those randomized to the routine care group...”

Oscars 2024: From Nominees to Red Carpet Glam! Get Exclusive Coverage on HT. Click Here

Catch your daily dose of Fashion, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs
SHARE THIS ARTICLE ON
Share this article
  • ABOUT THE AUTHOR
    author-default-90x90

    Rhythma Kaul works as an assistant editor at Hindustan Times. She covers health and related topics, including ministry of health and family welfare, government of India.

SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, March 28, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On